Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Cash from Financing Activities (2023 - 2025)

Historic Cash from Financing Activities for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to $352000.0.

  • Inhibrx Biosciences' Cash from Financing Activities changed N/A to $352000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $100.2 million, marking a year-over-year increase of 3812.35%. This contributed to the annual value of $71.7 million for FY2024, which is 6450.9% down from last year.
  • According to the latest figures from Q3 2025, Inhibrx Biosciences' Cash from Financing Activities is $352000.0.
  • Inhibrx Biosciences' 5-year Cash from Financing Activities high stood at $199.9 million for Q3 2023, and its period low was $352000.0 during Q3 2025.
  • Moreover, its 3-year median value for Cash from Financing Activities was $35.8 million (2024), whereas its average is $62.1 million.
  • The largest annual percentage gain for Inhibrx Biosciences' Cash from Financing Activities in the last 5 years was 15779.8% (2025), contrasted with its biggest fall of 15779.8% (2025).
  • Quarter analysis of 3 years shows Inhibrx Biosciences' Cash from Financing Activities stood at $860000.0 in 2023, then surged by 3731.4% to $32.9 million in 2024, then tumbled by 98.93% to $352000.0 in 2025.
  • Its Cash from Financing Activities was $352000.0 in Q3 2025, compared to $99.8 million in Q1 2025 and $32.9 million in Q2 2024.